NCT05036434View on ClinicalTrials.gov

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Pembrolizumab / Lenvatinib

Pembrolizumab Plus Lenvatinib administration.

Trial Locations (1)

10408

National Cancer Center, Goyang-si

All Listed Sponsors
collaborator

MSD Korea Ltd.

INDUSTRY

lead

National Cancer Center, Korea

OTHER_GOV